LL-37 — Human Cathelicidin for Antimicrobial and Wound Biology Research. Physician-Supervised
LL-37 is the only known human cathelicidin — a naturally occurring antimicrobial peptide produced by neutrophils, epithelial cells, and other immune cells as part of the body’s first-line defence against infection. Beyond antimicrobial activity, it has been studied for its role in wound healing biology, including keratinocyte migration, angiogenesis, and immune modulation. It is available at OptiMale USA following clinical assessment.
WHAT IS IT?
Understanding LL-37
LL-37 is produced from the human cathelicidin precursor protein hCAP-18. It is a 37 amino acid cationic peptide that disrupts bacterial cell membranes through electrostatic interaction — a mechanism that makes it effective against a broad spectrum of bacteria, fungi, and even some viruses in research settings. Beyond its antimicrobial function, LL-37 also acts as a signalling molecule that stimulates skin cells (keratinocytes) to migrate and proliferate, promotes angiogenesis, and modulates inflammatory signalling in wound tissue.
Research has examined LL-37 in wound healing biology — particularly in skin and mucosal tissue — for its combined antimicrobial and repair-promoting properties. It has also been studied in the context of chronic wound management, biofilm disruption, and immune signalling. At OptiMale USA, LL-37 is discussed for men with specific wound healing or skin tissue biology goals following thorough assessment. Administration is typically topical for skin applications or subcutaneous injection for deeper tissue contexts.
Quick Facts
Injection
Timeline: Immune support effects within 1–2 weeks; wound healing and infection management over 4–8 weeks
Lab required: Yes
Ongoing maintenance: Protocol-dependent
Pricing: Contact for Pricing
Related Treatments
Benefits
Broad-spectrum antimicrobial research
LL-37 disrupts bacterial cell membranes through a mechanism different from conventional antibiotics — targeting membrane integrity rather than specific bacterial metabolic processes. Research has studied this activity across a wide range of bacterial species and also examined antifungal and antiviral properties in preclinical models.
Keratinocyte migration and skin repair research
Beyond antimicrobial activity, LL-37 has been studied for its effects on keratinocyte — skin cell — migration and proliferation. Research has examined this in wound closure biology, investigating how LL-37 stimulates the movement of skin cells to cover wound surfaces.
Wound angiogenesis research
LL-37 has been investigated for its ability to promote new blood vessel formation in wound tissue — an important step in wound healing that restores oxygen and nutrient delivery to repair cells. This angiogenic activity has been studied alongside its keratinocyte effects in wound biology research.
Immune modulation in wound context
Research has examined LL-37's role in modulating inflammatory signalling in wound tissue — both recruiting relevant immune cells to the site and helping regulate the inflammatory response as repair progresses. This dual role as antimicrobial agent and immune modulator is a distinctive characteristic of LL-37's research profile.
Who Is This For?
Am I a Good Candidate?
Ideal For
- Men with wound healing concerns or chronic skin tissue issues who have been assessed by a licensed provider
- Men with susceptibility to skin infection or compromised wound healing in the context of their broader health profile
- Men whose clinical assessment identifies specific skin or mucosal tissue biology as a relevant focus
- Men who have completed a full assessment at OptiMale USA and for whom LL-37 is clinically discussed
Not Recommended If
- Men with active malignancy — LL-37’s cell proliferation effects are a consideration with cancer
- Men with autoimmune skin conditions that could be exacerbated by immune modulation
- Men who have not been assessed by a licensed OptiMale USA provider
- Men under 18
Safety
Potential Side Effects
LL-37 is endogenously produced by the human body, which contributes to its tolerability profile. Exogenous administration is less well characterised in formal human trials. All OptiMale USA patients are monitored throughout with clinical check-ins.
- Local tissue response — for topical applications, skin tolerability tracked at each check-in
- Inflammatory markers — assessed as part of standard follow-up bloodwork
- Clinical response — wound healing progress and any new symptoms reviewed at each appointment
- Local skin irritation with topical use — redness or mild stinging, typically transient
- Injection site reactions with subcutaneous use — mild redness or swelling
- Mild systemic inflammatory response — rare, typically self-resolving
Common Questions
Frequently Asked Questions
Is LL-37 the same as antibiotics?
No — LL-37 disrupts bacterial membranes through a physical mechanism different from the metabolic targets of conventional antibiotics. This membrane-disruption mechanism has been studied as potentially less prone to bacterial resistance development than conventional antibiotic targets. However, LL-37 is a research compound in this context and should not be considered a replacement for conventional antibiotic therapy. Your provider will discuss appropriate use within your clinical situation.
How is LL-37 administered?
For skin and wound applications, LL-37 is typically applied topically as a solution or cream directly to the relevant tissue. For deeper tissue applications, subcutaneous injection may be recommended. The appropriate route is determined by your provider based on the specific tissue and clinical goals involved.
Can LL-37 be combined with other wound healing peptides?
LL-37 and BPC-157, for example, have overlapping wound healing research contexts but different mechanisms — LL-37 focuses on antimicrobial activity and keratinocyte biology; BPC-157 on angiogenesis and GH receptor signalling. Whether combining them is appropriate for your specific wound or tissue biology goals is a clinical discussion with your provider during your consultation.
Get started
Discuss LL-37 With a Provider
Your free consultation is the first step. A licensed OptiMale USA provider will review your bloodwork, health history, and goals before making any recommendations.